Cue Biopharma to Host Business Update Call and Webcast
August 10, 2021 08:00 ET
|
Cue Biopharma, Inc.
CAMBRIDGE, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to...
Cue Biopharma to Present Corporate Update at the Upcoming BTIG Virtual Biotechnology Conference
August 03, 2021 08:00 ET
|
Cue Biopharma, Inc.
CAMBRIDGE, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to...
Cue Biopharma to Present at the Upcoming JMP Securities Life Sciences Conference
June 14, 2021 08:00 ET
|
Cue Biopharma, Inc.
CAMBRIDGE, Mass., June 14, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to...
Cue Biopharma Announces First Patient Dosed in Part B Patient Expansion of CUE-101 Phase 1 Monotherapy Trial in HPV+ Second Line and Beyond HNSCC
June 10, 2021 08:00 ET
|
Cue Biopharma, Inc.
CAMBRIDGE, Mass., June 10, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to...
Cue Biopharma to Present at the 2021 Federation of Clinical Immunology Societies (FOCIS) Virtual Annual Meeting
June 03, 2021 08:30 ET
|
Cue Biopharma, Inc.
CAMBRIDGE, Mass., June 03, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to...
Cue Biopharma to Present a Corporate and Clinical Progress Update at the Upcoming Jefferies Virtual Healthcare Conference
May 26, 2021 08:00 ET
|
Cue Biopharma, Inc.
CAMBRIDGE, Mass., May 26, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to...
Cue Biopharma Reports First Quarter 2021 Results, Recent Updates of CUE-101 Phase 1 Dose Escalation Study, Platform Progress and Business Highlights
May 17, 2021 16:01 ET
|
Cue Biopharma, Inc.
CAMBRIDGE, Mass., May 17, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively...
Cue Biopharma to Host Business Update Call and Webcast
May 10, 2021 10:00 ET
|
Cue Biopharma, Inc.
CAMBRIDGE, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to...
Cue Biopharma Reports Confirmed Partial Response (PR) in Ongoing Phase 1 Monotherapy Study of CUE-101 in Late Stage Second Line and Beyond Patients with HPV+ Recurrent/Metastatic Head and Neck Cancer
May 10, 2021 08:00 ET
|
Cue Biopharma, Inc.
And Provides Interim Clinical Data Update Partial response data demonstrates activity of CUE-101 as monotherapy in patient with human papilloma virus positive recurrent/metastatic head and neck...
Cue Biopharma to Present at the 2021 Frontiers in Cancer Immunotherapy Conference
May 06, 2021 08:00 ET
|
Cue Biopharma, Inc.
CAMBRIDGE, Mass., May 06, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to...